Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 11224 shares trading hands. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Stock Up 50.0 %
The company has a quick ratio of 0.46, a current ratio of 0.07 and a debt-to-equity ratio of 138.88. The company’s fifty day simple moving average is C$0.02 and its 200 day simple moving average is C$0.02. The firm has a market capitalization of C$1.99 million, a PE ratio of -1.50 and a beta of 0.05.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Further Reading
- Five stocks we like better than Aequus Pharmaceuticals
- Investing in Commodities: What Are They? How to Invest in Them
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- What is an Earnings Surprise?
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What Are Some of the Best Large-Cap Stocks to Buy?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
